Kefiran is an exopolysaccharide produced by Lactobacillus kefiranofaciens, and has been proposed to have many health-promoting properties. We investigated the antiatherogenic effect of kefiran on rabbits fed a high-cholesterol diet. Methods: Male New Zealand White rabbits were fed a 0.5% cholesterol diet without (control group, n 7) or with kefiran (kefiran group, n 8) for eight weeks. The aorta was analyzed by histochemistry and atherosclerotic lesions were quantified. Lipids and sugars in serum were measured. Foam cell formation of RAW264.7 by VLDL derived from both groups of rabbits was also investigated. Results: Cholesterol, triglyceride and phospholipids levels of serum and lipoprotein fractions were not significantly different between these groups. Atherosclerotic lesions of the aorta in the kefiran group were statistically lower than those of the control group, with marked differences in the abdominal aorta. T-lymphocytes were not detectable in the aorta of the kefiran group. Cholesterol contents in stools were almost identical in both groups. Cholesterol content in the liver of the kefiran group was statistically lower than in the control group. Galactose content of VLDL derived from the kefiran group was higher, and the lipid peroxidation level was much lower than in the control group. RAW264.7 macrophages treated with VLDL from the kefiran group showed a more spherical shape and accumulated statistically lower cholesterol than macrophages treated with VLDL from the control group. Conclusion: Orally derived kefiran is absorbed in the blood. Kefiran prevents the onset and development of atherosclerosis in hypercholesterolemic rabbits by anti-inflammatory and anti-oxidant actions. J Atheroscler Thromb, 2010; 17:980-988.
Introduction
Kefir is a popular fermented milk in the Caucasus region that uses kefir grains as a starter, and for which many health-promoting properties have been proposed 1) . Kefiran is an exopolysaccharide produced by Lactobacillus kefiranofaciens that is isolated from kefir grains, and has a repeating hexasaccharide structure with a [Glc-Gal(-Glc)-Gal-Gal-Glc]n branch. The molecular weight of kefiran is about 1 10 6 to 4
hypothesize that kefiran may promote catabolism and have anti-inflammatory effects. Kefiran is expected to prevent atherogenesis because it has hypocholesterolemic 4, 5) , hypotensive 2, 8) and anti-inflammatory effects 11) . When rabbits were fed a high-cholesterol diet for 8 − 12 weeks, levels of beta-very-low-density lipoprotein ( VLDL) were elevated and a large area of atherosclerotic lesions developed 12, 13) . We therefore investigated the effects of kefiran on atherogenesis in New Zealand White rabbits fed a 0.5% cholesterol diet.
Materials and Methods

Kefiran
"Rice kefiran" denotes a sterilized mixture of pure kefiran and L. kefiranofaciens bacteria cultured in rice medium 3) . Rice kefiran (Kefiran CR; Daiwa Pharmaceutical Company Limited, Tokyo, Japan) is a powder of dried culture filtrate containing 14% kefiran produced in a hydrolyzed rice medium by L. kefiranofaciens.
Rabbits and Food
The care, maintenance, and experimentation of animals were carried out according to the "Principles of Laboratory Animal Care" (NIH publication number 85 − 23, revised 1985) and the Guidelines of the Animal Investigation Committee of Chiba University (Chiba, Japan).
Male New Zealand White rabbits (6 weeks, 1.8 − 2.1 kg) were obtained from Takasugi Experimental Animal Supply Co., Ltd. Rabbits were randomly divided into two groups. The control group (n 7) was fed rabbit chow (RC) (normal rabbit chow; Oriental Yeast Co., Ltd., Tokyo, Japan) containing 0.5% cholesterol and 1% dextrin, and the kefiran-treated group (n 8) was fed RC containing 0.5% cholesterol and 7% rice kefiran (final concentration of kefiran, 1%). One percent dextrin was added to the control diet to ensure the equivalent number of calories as 1% kefiran 8) . These supplemented diets were prepared by Oriental Yeast Co., Ltd. Rabbits were fed a 100 g diet every day for 8 weeks.
Preparation of VLDL from Rabbit Serum
Blood was prepared after feeding for 8 weeks. Rabbits were fasted for one day before blood sampling and were anesthetized with an injection of pentobarbital (50 mg/kg, i.p.). Blood was drawn from the carotid artery and collected into sterile plastic tubes. Blood samples were centrifuged at 3,000 rpm in a refrigerated bench-top centrifuge for 10 min at 4 . VLDL (density 1.006 g/mL) was prepared from the serum of two groups of rabbits 14) .
High-Performance Liquid Chromatography (HPLC) Analysis of Lipoprotein Profile
Serum samples (100 L) were obtained from all rabbits after feeding for 8 weeks. Levels of total cholesterol (TC), free cholesterol (FC), triglyceride (TG) and phospholipids (PLs) of each of the major lipoprotein classes (chylomicrons, VLDL, low-density lipoprotein (LDL) and high-density lipoprotein (HDL)), in the pool sera were analyzed by HPLC at Skylight Biotech, Incorporated (Tokyo, Japan) 15) .
Lesion Analysis
After blood collection, aortas were perfused in situ with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde. Aortas were excised and stored at 4 . After removal of connective tissue, aortas were opened longitudinally. Atherosclerotic lesions of the entire aorta were measured using a computer-based image analyzer system (Luzex 3U; Nireco, Tokyo, Japan). The aorta was divided into four segments, as shown in Fig. 1A : the ascending aortic arch (site 1); the downstream region of the left subclavian artery (site 2); the aorta of the intermediate region between the left subclavian artery and the diaphragm (site 3); and the abdominal aorta under the diaphragm (site 4). The portion of each segment showing the most severe lesions shown in Fig. 1 was removed, embedded in paraffin by a standard method, and sectioned into 6 m serial sections.
Chemical Staining and Histological Analyses
Frozen sections of the aorta were stained with 0.1% (wt/vol) Oil Red O or Masson trichrome stain. The sections stained with Oil Red O were used for measurement of intimal lesions.
Paraffin sections were used for immunohistochemistry. Brown staining using chromogen diaminobenzidine (DAB) was performed using a Pathostain ABC-POD (M) kit (Wako Pure Chemical Industries Ltd, Tokyo, Japan) following the protocol provided by the manufacturer. Monoclonal human endothelial CD31 antibody (Clone JC70A), monoclonal-smooth muscle cell actin antibody (Clone 1A4), and rabbit macrophage marker (RAM-11) were purchased from Dako; monoclonal rabbit T-lymphocyte marker-CD43 antibody (Clone L11/135) was purchased from AbD Serotec. All primary antibodies (dilution 1: 100 − 200) were incubated overnight. Mouse serum (diluted 1: 100) was used as the negative control. Slides were counterstained with hematoxylin, blued in Scott's tap water, dehydrated, and mounted in Di-n-butylphthalate in xylene (DPX) medium.
Extraction of Cholesterol from Feces and the Liver and Measurement of Cholesterol
Livers were stored at 80 until use. One hundred milligrams of each liver was homogenized with 1 mL SET buffer (0.25 M sucrose, 1 mM ethylene diamine tetra-acetic acid (EDTA), 50 mM Tris HCl, pH 7.4), and the liver samples were added to 10 mL of 2: 1 chloroform/methanol to extract cholesterol. Feces were collected from the segment of the large intestine closest to the anus, and completely dried in an oven set at 80 . Dried feces (0.5 g) were crushed, added to 10 mL chloroform: methanol (2: 1), and mixed well. Dried feces (1.5 g) from each rabbit were used and the extractions mixed. The extracted chloroform solutions from the liver and feces were dried and dissolved in Cholesterol E-test Wako kit buffer (Wako, Tokyo). TC and FC contents were measured by the Cholesterol E-test Wako kit and Free Cholesterol E-test Wako kit, respectively.
Determination of Lipid Peroxide
Hydroperoxide content in VLDL as lipid peroxide was determined using a Determiner LPO kit (Kyowa Medex Company Ltd).
Analysis of Monosaccharide Composition
In order to extract saccharide from 1 mL of each sample, 1 mL n-hexane was added and vortex-mixed. The preparation method and HPLC conditions for analysis of monosaccharide composition were described in a previous report 16) .
Formation of Macrophage Foam Cells
RAW264.7 mouse peritoneal macrophages (American Type of Cell Culture) were maintained in 12-well culture plates in Dulbecco's modified Eagle's medium (DMEM; Iwaki) containing 10% fetal bovine serum (FBS). Cells were cultured with or without VLDL (2 cholesterol mg*mL 1 ) derived from rabbits for 24 h. Cells were fixed with 4% paraformaldehyde and stained with hematoxylin-eosin. Cell lipids were extracted by hexane: 2-propanol (2: 1). Lipid extracts were transferred to 96-well plates with 1% Triton X-100/EtOH. TC and FC contents were measured by the Cholesterol E-test Wako kit and Free Cholesterol E-test Wako kit, respectively.
Determination of Protein Concentrations
Protein concentrations were determined using a bicinchoninic acid (BCA) protein assay reagent kit (Pierce) using bovine serum albumin as the standard.
Statistical Analysis
The statistical significance of differences was assessed by the unpaired t -test using JSTAT.
Results
Serum Cholesterol Level
There was no difference in body weight between the two groups. The initial body weights of control and kefiran groups were 1.95 0.08 kg and 1.94 0.08 kg, respectively. The weights at the end of the experiment were 2.64 0.17 kg and 2.61 0.13 kg, respectively. Table 1 shows the levels of TC, FC, TG and PL Rabbits were a fed a 0.5% cholesterol diet (control) and 0.5% cholesterol plus kefiran diet (kefiran). Measurement of surface area (A) and intimal lesion (B), and calculation of the percentage of atherosclerotic lesions in each A B levels in serum and lipoprotein fractions. Many values in the kefiran group were lower than in the control group, but statistically significant differences between the two groups were not observed.
Reduction in the Size of Atherosclerotic Lesions with Kefiran Treatment
Lesions on the surface of the aorta were measured to clarify whether kefiran intake reduced the size of atherosclerotic lesions (Fig. 1A) . The total area of lesions in the kefiran group was significantly lower than in the control group. Atherosclerotic lesions close to the heart (site 1) were well developed in both groups; the number of atherosclerotic lesions gradually decreased in aortic regions further away from the heart. Fig. 1B shows Oil Red O staining of tissue sections from sites 1 − 4 in Fig. 1A . There was no significant difference in the area of atherosclerotic lesions at site 1, which was closest to the heart, between control and kefiran groups. The area of atherosclerotic lesions in sites 2, 3 and 4 of the kefiran group were significantly decreased compared with those of the control group. Fig. 2 shows the results of Masson trichrome staining and immunohistochemical analysis of the sections of site 3 in control and kefiran groups. In the control group, the intimal lesion was deficient in fibrous tissue ( Fig. 2A) and rich in macrophages (Fig. 2E) . The inner layer of the intima was positive for smooth muscle cells (Fig. 2G) and was covered by endothelial cells (Fig. 2C) . T-lymphocytes were also detected in the sections of site 3 ( Fig. 2I ) and site 4 (data not shown), but were not detected in site 1 and site 2 (data not shown). The sections of site 3 in control groups showed the typical pathology for atherosclerosis. Site 3 of the kefiran group showed very small atherosclerotic lesions that may be the initial stage of the lesion process. The small atherosclerotic lesion was positive for macrophages and T-lymphocytes (Fig. 2F,  2J ), but positive staining for T-lymphocytes was not detected in all other sections in kefiran groups (data not shown). We hypothesize that these inflammatory events may be strongly suppressed in the kefiran group, and that kefiran may prevent the onset and/or development of atherosclerosis.
Chemical Staining and Histological Analyses
Cholesterol Content in Stools and the Liver FC contents in stools were measured to clarify whether kefiran prevents the absorption of FC in food from the intestine (Fig. 3A) . There was no difference between control and kefiran groups, suggesting that kefiran did not influence the absorption of cholesterol from chow. Next, cholesterol contents in the liver were measured to assess the effect of kefiran on cholesterol metabolism in this organ (Fig. 3B) . Levels of TC, FC and cholesteryl ester of the liver in the kefiran group were significantly reduced compared with those in the control group, suggesting that cholesterol catabolism may be promoted in the kefiran group.
Presence of Galactose and Lipid Peroxide
It is not known if kefiran is taken up into cells. The mechanism of how kefiran suppresses atherosclerosis in rabbits is also unknown. Levels of glucose and Cross-sections were prepared from site 3 of the aortas of control and kefiran groups. Panels A and B, Masson trichrome staining; panels C and D, immunostaining using anti-endothelial CD31 antibody (JC70A); panels E and F, immunostaining using antimacrophage antibody (RAM11); panels G and H, immunostaining using anti-smooth muscle actin antibody (1A4); panels I and J, immunostaining using monoclonal rabbit T-lymphocyte marker-CD43 antibody (Clone L11/135). Panels A, C, E, G and I were sections from the control group and panels B, D, F, H and J were from the kefiran group. Scale bar denotes 200 m in each photograph. Brown area is positive immunostaining and blue area is nuclear staining produced with hematoxylin. A B galactose were measured in serum because kefiran is composed of these compounds ( Table 2) . Glucose levels in the serum of control and kefiran groups were identical. Galactose was not detected in the serum of either group. Levels of glucose and galactose in VLDL derived from the kefiran group were significantly higher than those of the control group, suggesting that kefiran may be taken up by cells and concentrated into VLDL in the kefiran group. It was expected that kefiran may influence VLDL, so the degree of oxidation of the latter was measured ( Table 2) . The level of lipid peroxide of VLDL in the kefiran group was only about 18% of that of the control group.
Effect of VLDL Prepared from the Kefiran Group on RAW264.7 Macrophages
The lipid peroxide level of VLDL prepared from the kefiran group was quite low, so the effect of VLDL from both groups on RAW264.7 macrophages was investigated. Cell morphology was changed after RAW264.7 macrophages were treated with VLDL (Fig. 4A) ; RAW264.7 macrophages incubated with VLDL from the control group had a spindle shape. Cells had a spherical shape when RAW264.7 macrophages were treated with VLDL from the kefiran group. TC, FC and cholesteryl ester content in RAW264.7 macrophages treated with VLDL from the kefiran group were significantly lower than those in cells incubated with VLDL from the control group (Fig. 4B) .
Discussion
Kefiran intake greatly reduced the size of atherosclerotic lesions in cholesterol-fed rabbits. It has been believed that water-soluble dietary fiber is not absorbed and has a unique physiological function in the intestine 10) . Our results suggest that kefiran (or its components) was absorbed into the blood and may influence atherogenesis because galactose was present in VLDL.
Intact kefiran in VLDL was not detected by enzyme-linked immunosorbent assay, (ELISA), which can detect intact kefiran (data not shown). This indicates that kefiran had been digested in the body and converted to oligosaccharide. Glucose and galactose contents in VLDL were significantly increased in the kefiran group, but serum glucose was similar in the two groups and serum galactose was not detected in either group ( Table 2) . The major pathway for galactose metabolism is considered to be the conversion of galactose to glucose by Gal-1-P, UDP-gal, and glucose-1-P. This conversion of galactose to glucose can be enhanced by glucose via an increase in the activity of galactose-1-phosphate uridyltransferase (GALT) in the liver and also via the action of insulin 17) . If there is a block in either step, galactosemia occurs, which can cause disorders such as ovarian dysfunction or cirrhosis 18) . If galactose is present as a monosaccharide in VLDL and the liver, galactose should be converted to glucose by GALT. Galactose was probably present as an oligosaccharide because serum galactose was not detected. These findings suggest that kefiran may be digested to an oligosaccharide, and that the oligosaccharide may be present in VLDL. VLDL is released from the liver, so VLDL, including the oligosaccharide derived from kefiran, may be present in the liver.
It has been reported that kefiran lowers blood cholesterol in SHRSP rats 2, 8) . In this report, the mean TC level was statistically decreased to 90.9% in SHRSP rats given 0.3 g kefiran/kg by gastric intubation with a high fat diet compared to control group. In our study, mean TC levels in serum and VLDL, from rabbits fed about 0.5 g kefiran/kg in a 0.5% cholesterol diet, were decreased to 84.5% and 80.2%, respectively, compared to the control group ( Table 1) . Although there were no statistically significant differences between the two groups because of relative large standard deviations, it is expected that kefiran intake may decrease serum lipid levels in rabbits.
Atherogenesis is an inflammatory process accompanied by the recruitment and activation of immune cells, such as T-lymphocytes 19, 20) . The effects of oligo- ; human milk and schistosome oligosaccharides secrete anti-inflammatory cytokines that suppress T-helper type cells and the inflammatory response 22) . Intragastric administration of kefiran prevented ovalbumin-induced lung inflammation in a murine model of asthma 11) . In our model, detection of T-lymphocytes was very low in the kefiran group, and the area of macrophage-positive atherosclerotic lesions in the kefiran group was reduced compared with those of control groups. Kefiran may inhibit lymphocyte activation, which might explain why atherosclerotic lesions were strongly suppressed in site 3 and site 4 in Fig. 1 , but lesions were not suppressed in site 1. Site 1, which was close to the heart, may have been strongly influenced by blood pressure. There was no difference in blood pressure between control and kefiran groups (data not shown), so the activation level of endothelial cells in site 1 may have been almost identical in both groups. Site 3 and site 4 may have been dependent on the activation level of T-lymphocytes to induce atherogenesis because these areas were far from the heart. The areas of atherosclerotic lesions in rabbits in the kefiran group were reduced if the activation level and cell number of lymphocytes were decreased by kefiran intake.
Macrophages take up VLDL, including oligosaccharide derived from kefiran, resulting in a change in the shape of macrophages and suggesting that oligosaccharide may change cell characteristics. Macrophages from human monocytes in FBS with macrophage-colony-stimulating factor (M-CSF) had a spindle shape and constitutive fluid-phase uptake of native . Macrophages, differentiated with granulocyte-macrophage (GM)-CSF macrophages, maintained a spherical shape, and accumulated cholesterol lower than M-CSF-treated macrophages when incubated with 2 mg/mL LDL for 24 h 24) . These data are quite similar to our data (Fig. 4) . Macrophages treated with M-CSF or GM-CSF showed different gene-expression patterns 24) , so it was expected that the pattern of gene and protein expression changed in RAW264.7 macrophages treated with VLDL from the kefiran group. These results suggest that exogenous oligosaccharide may have an effect on cellular function.
Milk kefir and soymilk kefir had high scavenging activity against 1,1-diphenyl-2-picrylhydrazyl (DPPH) radicals, an inhibition effect against linoleic acid peroxidation, and substantial reducing power 25) . It has been reported that wheat bran feruloyl oligosaccharides significantly increased the total antioxidant capacity (TAOC) level, and the activities of glutathione peroxidase (GSH-Px), and superoxide dismutase (SOD), but decreased levels of blood glucose and malondialdehyde (MDA) and xanthine oxidase (XOD) activity in the serum and liver of diabetic rats compared with diabetic controls. Feruloyl oligosaccharides also showed greater antioxidant capacity in vivo than in vitro when compared with vitamin C 26) . From these findings, it is expected that the much lower level of oxidation in VLDL from the kefiran group may depend on oligosaccharide derived from kefiranreducing oxidation in the serum and the liver. Oxidative lipoproteins induce the formation of foam cells [27] [28] [29] [30] [31] [32] [33] [34] , so macrophages treated with VLDL from the kefiran group accumulated less cholesterol and reduced the area of atherosclerotic lesions in the kefiran group.
The reason why kefiran intake reduced the area of atherosclerotic lesions in our experiments has three possibilities: (i) suppression of inflammation in the kefiran group, (ii) less accumulation of cholesterol in macrophages in the kefiran group, and (iii) lower serum lipid levels in the kefiran group. Another issue is the change in cholesterol metabolism in the liver. Oligosaccharide derived from kefiran is assumed to be present in VLDL, so oligosaccharides were already allowed into hepatocytes after kefiran intake. These oligosaccharide may then influence the reduction of cholesterol content in the liver, but the mechanism is not known. The pathway by which kefiran reaches the liver is also not known: was kefiran absorbed intact or were its decomposition products absorbed after intestinal digestion ? Although radioactive kefiran by oral administration is known to be distributed in organs such as the liver, kidney urinary bladder etc. 35) , whether kefiran enters cells lining the intestine, macrophages, or dendritic cells is also not known. The monocyte/ macrophage cell lines, U937 and J774.1 cells, bind and internalize water-soluble pharmaceutical grade (1 − 3)-beta-D-glucan phosphate 36) . Dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin (SIGN)-R1-transfected cells take up mannose conjugates and dextran conjugates 37) . Macrophages could possibly take up a large molecule in sugar chains.
Kefiran intake decreased the size of atherosclerotic lesions in hypercholesterolemic rabbits and did not show adverse effects in these animals. Our findings show that kefiran is a healthy food that may inhibit atherogenesis.
